CLINICAL_TRIALS ClinicalTrials.gov record update

A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01109069
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:41.983470+00:00
Published At: 2020-05-07T00:00:00+00:00
Record Updated At: 2020-05-27
Results Posted At: 2020-05-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["B-cell Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Diffuse Well-differentiated Lymphocytic Lymphoma", "B Cell Lymphoma", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Non-Hodgkin\u0027s Lymphoma", "Waldenstrom Macroglobulinemia", "Burkitt Lymphoma", "B-Cell Diffuse Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-05-27"
protocolSection.identificationModule.nctId: "NCT01109069"
protocolSection.identificationModule.officialTitle: "A Long-term Safety Study of Bruton\u0027s Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-05-07"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.